Alpha Cognition (ACOG) vs Invivyd (IVVD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Alpha Cognition (ACOG) has outperformed Invivyd (IVVD) over the past year, gaining 17.1% versus a loss of 57.3%. Invivyd is the larger company by market cap ($206.4 million vs $196.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACOG | IVVD |
|---|---|---|
| Share price | $9.04 | $0.7004 |
| Market cap | $196.87M | $206.45M |
| 1-day change | 0.00% | -3.87% |
| YTD return | +39.08% | -71.64% |
| 1-year return | +17.10% | -57.29% |
| 5-year return | — | -97.84% |
| EPS (TTM) | $-1.33 | $-0.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.14 | $3.07 |
| 52-week low | $4.50 | $0.528 |
| Distance from 52-week high | -10.85% | -77.19% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +99.12% | +1327.76% |
| Average volume | 125.72K | 4.78M |
| Shares outstanding | 21.78M | 294.76M |
| Employees | 71 | 122 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACOG has outperformed IVVD by 74.4 percentage points over the past year.
About Alpha Cognition
ACOG stock →Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease.
Healthcare · Biotechnology · 71 employees
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Healthcare · Biotechnology · 122 employees
ACOG vs IVVD FAQ
Which is bigger, Alpha Cognition or Invivyd?
Invivyd (IVVD) is larger, with a market capitalization of $206.45M compared with $196.87M for Alpha Cognition (ACOG).
Which stock has performed better over the past year, ACOG or IVVD?
ACOG returned +17.10% over the past 12 months, compared with -57.29% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are Alpha Cognition and Invivyd in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.